Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2021

View Archived Issues

Post-chemo bone marrow regeneration elucidated

Taiho begins phase II study of TAS-117 in advanced solid tumors with germline PTEN mutations

Roche initiates phase III study of glofitamab for relapsed or refractory DLBCL

Pain on the brain

Neurons contribute to their own lack of regeneration

Astrocytes are more inflammatory in bipolar disease

Headless hemagglutinin induces broad influenza antibodies

Study sponsors discontinue testing of razuprotafib in I-SPY COVID trial

CAUSALITY study of Xla-1 shows safety in healthy volunteers and starts enrolling obese patients

FDA approves phase III study of proxalutamide in COVID-19

Gene therapy for TMPRSS3 hearing loss shows promise with late intervention in mouse model

Neumifil is efficacious in hamster model of COVID-19 infection

CytoDyn reports phase III data on leronlimab in critically ill COVID-19 patients

Innovation studies brilacidin in phase II trial for hospitalized patients with COVID-19

Melatonin repairs PNI through activation of the Shh signaling pathway in Schwann cells

Roche patents mGlu4 receptor negative allosteric modulators

Aligos Therapeutics discloses new antivrals for hepatitis

BiSiChem identifies RIPK1 inhibitors

Anti-inflammatory peptide amphiphiles reduce inflammation in Crohn's disease-like ileitis model

Incyte discloses CDK2/cyclin E inhibitors

Crinetics Pharmaceuticals synthesizes new somatostatin SST5 receptor agonists

JTP-109192 shows cholesterol-lowering effect in hyperlipidemic mice

FDA grants accelerated approval to Yescarta for relapsed or refractory follicular lymphoma

Abivax stops phase IIb/III trial of ABX-464 in high-risk COVID-19 based on DSMB recommendation

Roche withdraws Tecentriq U.S. indication for prior-platinum treated metastatic urothelial carcinoma

REGN1908-1909 ameliorates bronchoconstriction in patients with cat-allergy asthma

Bavarian Nordic reports preclinical data on COVID-19 vaccine candidate ABNCoV2

Seres discontinues enrollment in MCGRAW study of SER-401 in metastatic melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...